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With the introduction of aflibercept, eyes with neovascular age-related macular degeneration (AMD) not responding well to
injections of ranibizumab or bevacizumab can be switched to treatment with aflibercept. We carried out a meta-analysis to analyze
all available evidence of visual and anatomical outcomes of eyes with resistant neovascular AMD switched to aflibercept at six
months. Data from seven retrospective and prospective studies looking at change in best corrected visual acuity (BCVA) and central
retinal thickness (CRT) were included. Weighted mean difference (WMD) and 95% CI were estimated using the standardized
mean change method.The overall results of the meta-analysis showed a small but statistically significant improvement in BCVA six
months following treatment switch to aflibercept (WMD 0.142, 95% CI 0.006 to 0.28; 𝑝 = 0.04), and the effect was more significant
in data gathered from prospective studies (WMD 0.407, 95% CI 0.023 to 0.791, 𝑝 = 0.038). There was a significant improvement in
CRT following treatment switch to aflibercept (WMD −0.36, 95% CI −0.485 to −0.235; 𝑝 < 0.0001). Our meta-analysis indicates
that following treatment switch to aflibercept patients may have a significant improvement in CRT with stabilization or even some
improvement in their visual acuity.
1. Introduction
Age-relatedmacular degeneration (AMD) is a chronic degen-
erative process and is the leading cause of severe vision loss
in people over the age of 60 in developed countries [1].
The neovascular (wet or exudative) form of AMD, which
accounts for approximately 10% of cases, results in rapid
deterioration in visual acuity often with permanent severe
loss of vision [2]. The identification of the pathophysiologic
mechanisms at the basis of neovascular AMD, particularly
the role of vascular endothelial growth factor (VEGF), has
led to the development and use of intravitreally delivered
anti-VEGF agents, which target and cause regression of
choroidal neovascularization [3, 4] and have become the
standard of care. Currently, there are three clinically avail-
able agents, ranibizumab (Lucentis, Genentech, South San
Francisco, CA), bevacizumab (Avastin, Genentech), and a
more recent addition aflibercept (Eylea, Regeneron, Tarry-
town, NY, USA). Each of these drugs has been tested in
large multicenter, randomized, controlled clinical trials and
found to have comparable effects on treatment of naı̈ve
patients [5–8]. To date, no clear evidence has been presented
demonstrating a significant difference between aflibercept
and any other agent for the treatment of either naı̈ve or
resistant neovascular AMD. Indeed, patients that are deemed
unresponsive to treatment with any one agent are regularly
offered an alternative drug. Treatment protocols with afliber-
cept also differ among studies, with a loading dose of three
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monthly injections followed either by a bimonthly or by a pro
re nata regimen. Recently, a study examining the response
to anti-VEGF treatment, using all three drugs, of patients
with diabetic macular edema demonstrated that eyes with
severe vision loss were more likely to benefit from the use of
aflibercept [9].This suggests that there may be a difference in
drug response among some patient subgroups.
In this paper we aimed to perform a meta-analysis of the
published literature on the efficacy of aflibercept in patients
with neovascular AMD resistant to previous treatment with
ranibizumab and/or bevacizumab. We evaluated the changes
in their visual acuity and central retinal thickness (CRT) fol-
lowing the switch to aflibercept.
2. Methods
2.1. Search Strategy. Major databases including PubMed
(MEDLINE), EMBASE, the Science Citation Index Expand-
ed, and the Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library were searched for
studies comparing visual acuity and/or change in CRT on
optical coherence tomography (OCT) of eyes with resistant
neovascular AMD on prior anti-VEGF treatment switching
to aflibercept, published in English from January 2012 toMay
2015. The medical search headings “ranibizumab,” “beva-
cizumab,” “Avastin,” “anti-VEGF,” “Lucentis,” “Aflibercept,”
“Eylea,” and combinations of these were used, so were the
keywords “persistent,” “resistant,” and “recurrent” and the
keywords “switching,” “transitioning,” and “conversion.”The
reference lists of articles identified were examined to find
additional relevant studies that had not been identified by
the database searches. We only included comparative clinical
studies with the same group of patients treated with anti-
VEGF prior to switching to aflibercept and that had full
text available in English. The final inclusion of articles was
determined by consensus between the authors SSG andOTN.
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-Analysis (PRISMA) guidelines in
designing, performing, and reporting the systematic review
[10]. Included studies were required to (1) assess visual
acuity and/or CRT of patients with persistent and resistant
neovascular AMD treated with one anti-VEGF drug and then
switched to aflibercept, (2) have a minimum follow-up of six
months after switching to aflibercept, (3) have the treatment
regimen used clearly stated, and (4) be published in English.
2.2. Data Extraction and Quality Assessment. Data were
extracted using standardized forms. Data recorded included
patient and study characteristics, BCVA, CRT, and statistics
used for the study. In order to evaluate the reliability of the
comparative evidence, two authors (SSG and OTN) indepen-
dently assessed the risk of bias of the included studies using a
modified version of the Newcastle-Ottawa Scale for assessing
the quality of prospective and retrospective studies in meta-
analysis [11, 12]. Each paper was awarded a score in four
categories, patient selection (0–3), treatment comparability
(0–6), statistical methods (0–3), and outcome (0–6). Studies
achieving ten or more points were considered to be of high
quality. Only these studies were included in the final analysis.
Prospective studies scored higher on patient selection than
retrospective studies as were multicenter studies, as they are
more likely to be representative of the entire patient popula-
tion. Use of fluorescein fundus angiography (FFA), OCT, or
combination of both received an increasingly higher score on
treatment comparability. Outcome and timing assessments
of best corrected visual acuity (BCVA) and CRT as well as
reporting of follow-up were all evaluated. For the purpose
of the analysis, all BCVA values were converted to the log
minimum angle of resolution (LogMAR).
2.3. Statistical Analysis. Original data were extracted from
the studies and analyzed and the standardized mean change
was used to calculate intervention effects. The standardized
mean change was used to compute the estimates of treatment
for correlated designs. The standardized mean change has
been shown to be amore appropriatemeasure of effect size for
the direct comparison of data from studies using a pretest and
posttest design without control groups [13–15]. For the pur-
poses of this meta-analysis, we used themean, standard devi-
ation (SD), and the correlation for pre/postswitching data. In
all studies, the correlation between pre- and postswitching
datawas not reported and valueswere obtained either directly
from the authors or by calculating the correlation using
the 𝑝 value/𝑡-test values, means, standard deviation, and
the number of patients included from the published data
[14]. Using these values we were then able to calculate the
standardized mean change for each group [15]. Studies for
which such information could not be obtained were excluded
from the meta-analysis (𝑛 = 5). The standardized mean
change was calculated as the difference between the means of
the posttreatment switching values and the baseline divided
by the pooled standard deviation. Five studies lacked enough
statistical information to be included in this meta-analysis
and their outcomes were reviewed for information only [16–
20]. Studies specific standardized mean change was pooled
using fixed effect models with the Mantel-Haenszel method
if heterogeneity was negligible or using random effect models
with theDerSimonian-Lairdmethodwhenheterogeneitywas
significant [21, 22]. Interstudies heterogeneity was assessed
using the Cochran 𝑄 test and 𝐼2 tests [22], with a 𝑝 < 0.05
and 𝐼2 > 50% suggesting a high interstudy heterogene-
ity. In an attempt to identify the source of heterogeneity
in the data, we performed a metaregression analysis on
confounders such as the type of study, the previous total
length of treatment, previous total number of anti-VEGF
injections prior to switching, and mean BCVA at baseline.
A 𝑝 value < 0.05 was regarded as significant results and all
tests were 2 sided. All statistical analyses were performed
using commercially available software comprehensive meta-
analysis (CMA, Biostat, Englewood, NJ, USA, v 3.0). The
estimates of treatment effect are presented as weighted mean
difference (WMD) and graphically as forest plots. Sensitivity
analysis was carried out by including only studies deemed
with a quality score of 90% or above (13 points and above)
and excluding each study from the analysis of each outcome
measure to confirm the stability of our findings. Publication
bias was assessed with the funnel plot and with the Egger test
[23].
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Table 1: Characteristics of all studies included in the Meta Analysis.
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3.1. Search Findings and Results Characteristics. The search
strategy initially generated 28 relevant clinical studies, of
which 13 scored higher than 10 on the quality assessment.
Of these, seven studies had sufficient outcome data and
statistical information to be included in the meta-analysis
(four retrospective studies [24–27] and 3 prospective studies
[28–30], Figure 1). All these studies were included in the
meta-analysis of visual and/or CRT following switching to
aflibercept, six studies in the analysis of BCVA (232 eyes
of 225 patients) [24–26, 28–30] and five in the analysis
of CRT (266 eyes of 259 patients) [24–28]. Table 1 details
study characteristics, quality, and comparability assessments,
and Table 2 shows the analyzed outcome measures. Median
patient age at time of treatment switching was 78 years (range
70.1–80.3 years), with a median female percentage of 55.96%
(range 30.9–70.5%). At the time of treatment switching
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Figure 1: PRISMA flow diagram of study selection.
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Group by
types of studies Study name
Statistics for each study
Std diff in means and 95% CIStd diff Lower Upper Relative 
in means limit limit p value weight
Prospective Singh et al. 0.731 0.298 1.163 0.001 28.65
Prospective Chang et al. 0.501 0.204 0.798 0.001 35.47
Prospective Wykoff et al. 0.055 −0.234 0.344 0.708 35.87
Prospective 0.407 0.023 0.791 0.038
Retrospective Kumar et al. 0.288 0.102 0.474 0.002 26.14
Retrospective Bakall et al. 0.071 −0.079 0.222 0.352 30.67
Retrospective Gharbiya et al. 0.015 −0.037 0.067 0.578 43.20
Retrospective 0.104 −0.042 0.249 0.162
Overall 0.142 0.006 0.277 0.041
−2.00 −1.00 0.00 1.00 2.00
Does not favour aflibercept
Random effects model
Heterogeneity I2 = 21.97% overall Favours aflibercept
Figure 2: Forrest plot of six studies reporting comparative results of best corrected visual acuity sixmonths after switching to aflibercept. Note
that for the prospective studies the accumulated effect demonstrated a significant improvement, which was not found for the retrospective
studies. The overall effect was found to be significant (𝑝 = 0.04). The lower and upper limits represent the 95% confidence interval.
Statistics for each study
Std diff in means and 95% CIStd diff Study name Standard Lower Upper
Relative
in means error limit limit p value weight
−0.768 0.190 −1.140 −0.396 0.000 9.42
−0.380 0.160 −0.693 −0.067 0.017 12.41
Messenger et al. −0.337 0.044 −0.423 −0.252 0.000 43.92
−0.321 0.091 −0.499 −0.142 0.000 26.07
−0.104 0.206 −0.508 0.301 0.615 8.17
−0.360 0.064 −0.485 −0.235 0.000
−2.00 −1.00 0.00 1.00 2.00
Favours aflibercept Does not favour aflibercept
Random effects model





Figure 3: Forrest plot of five studies reporting comparative results of the central retinal thickness (CRT) six months after switching to
aflibercept. The overall effect demonstrated a significant reduction in CRT. The lower and upper limit represents the 95% CI.
patients had been diagnosed with neovascular AMD for a
median of 40.65 months (range 20.5–44.1 months) and eyes
had already been given amedian of 28.6 anti-VEGF injections
(range 9.6–42.0 injections).Themedian time between the last
anti-VEGF injection and beginning of aflibercept treatment
was 35.0 days (range 33.3–46.5 days) and eyes were treated
with a median of 5.1 aflibercept injections (range 4.50–5.60
injections). The median BCVA at baseline was 0.53 LogMAR
(range 0.32–0.64 LogMAR) and CRT on OCT was 413 𝜇m
(range 336.3–448.3 𝜇m).
3.2. Best Corrected Visual Acuity (6 Studies). The overall
results of the meta-analysis showed a small but statistically
significant improvement in BCVA at six months after switch-
ing to aflibercept (WMD 0.142, 95% CI 0.006 to 0.28; 𝑝
= 0.04). The random model was used as heterogeneity of
the data (𝐼2) was 81.02%. Exploring possible confounders
on BCVA we performed a weighted regression on the six
studies included. The type of study design was the only
moderator that showed a significant effect on the BCVA
at six months (𝑄 = 8.71, 𝑝 = 0.003), with prospective
studies demonstrating a greater estimate of treatment effect
on change in BCVA (WMD 0.407, 95% CI 0.02 to 0.79,
𝑝 < 0.038, Figure 2) than retrospective studies (WMD 0.104,
95% CI −0.04 to 0.25; 𝑝 = 0.16). Other covariates such
as mean number of anti-VEGF injections prior to switching
to aflibercept, length of time of treatment with anti-VEGF
prior to switching, mean BCVA at switching, and the type of
treatment had no effect on the overall results.
3.3. Central Retinal Thickness (5 Studies). Overall, patients
with their current treatment resistant AMD had a significant
improvement in CRT at six months following switching to
aflibercept (WMD −0.36, 95% CI −0.49 to −0.24; 𝑝 < 0.0001,
Figure 3). The random model was used as heterogeneity of
the data (𝐼2) was 66.79%. The weighted regression on the 5
studies included for covariates (mean number of anti-VEGF
prior to switching to aflibercept, total length of treatmentwith
anti-VEGF prior to switching, mean BCVA at switching, and
mean CRT at switching) showed no significant effect on CRT
at 6 months.
3.4. Sensitivity and Subgroup Analysis. We performed a
sensitivity analysis, to determine the effect of each study on
6 Journal of Ophthalmology
the overall result, by removing each of the studies one at
a time and recalculating the summary WMD. The overall
pooled WMD remained stable indicating that our results
were not influenced by any single study. We performed a
further sensitivity analysis of all studies scoring above 90%
of the maximal score (13 points and above, WMD 0.204, CI
from 0.012 to 0.395, 𝑝 = 0.037) and excluding each study
from the analysis of each outcomemeasure [26, 28–30].These
exclusions did not alter the results obtained in the overall
analysis.
3.5. Publication Bias. We assessed possible publication bias
with a funnel plot (not shown). Although the funnel plot
showed evidence of publication bias, the small number of
studies limits this analysis, as confirmed by Egger’s test (𝑝 =
0.03). The same tests did not suggest publication bias for the
anatomical outcome (𝑝 = 0.43).
4. Discussion
This study systematically reviewed and analyzed the evidence
in the literature of the effect of switching to treatment
with aflibercept in eyes with neovascular AMD resistant to
previous anti-VEGF treatment. Overall, we included four
retrospective and three prospective studies that had a follow-
up period of at least six months (three retrospective studies
had a follow-up period of up to twelve months). While we
were able to identify other studies that examined the effect
of switching to aflibercept, insufficient outcome information
prevented these from being included in this analysis.
Our meta-analysis demonstrated a small but significant
improvement in BCVA following switching to aflibercept.
While this improvement in BCVA was indeed small and of
limited clinical significance, it was driven by a significant
improvement noted in the analyzed prospective studies
(ranging between 0.1 and 0.14 LogMAR), suggesting that the
retrospective design of the studies where no effect was found
may have influenced their outcome.
The metaregression analysis did not demonstrate any
effects on BCVA from confounders such as mean number of
anti-VEGF injections, mean length of treatment or the drug
used prior to switching, which is in keeping with results from
other studies [19, 27]. While most studies used a standard
treatment protocol following switching, of a loading dose of
three monthly injections followed by a bimonthly regime,
other studies used a pro re nata regimen, neither of which
resulted in a difference in treatment effect.
The results of this meta-analysis demonstrated a signif-
icant improvement in CRT following the treatment switch
to aflibercept. This was a consistent finding in all the studies
and was maintained during the longer follow-up up to twelve
months [27, 31, 32]. While there was a definite improvement
in retinal thickness, this did not correlate with significant
restoration of visual function. Repeated use of any drug can
result over time in tachyphylaxis with resultant loss of clinical
effect [33–35], which can often be overcome by switching
to another drug with an alternative mode of action. Thus,
restoration of effect may be achieved following switching,
resulting in clearing of retinal fluid and reduction in CRT.
However, the lack of a concomitant gain in visual function
suggests it may be related either to an accumulating effect of
long term neovascularization, such as development of retinal
gliosis, or to progression of retinal atrophic changes that have
been documented to occur in neovascular AMD eyes treated
with anti-VEGF injections [36–38].
While this meta-analysis included all current studies
examining treatment switching to aflibercept in eyes with
neovascular AMD, it nevertheless suffers from several limi-
tations, mainly related to the quality of the studies analyzed.
Most studies performed to date were nonrandomized ret-
rospective treatment comparison studies, which introduce
potential confounding biases due to an inability to adjust
for patient baseline demographic characteristics or disease
severity.Though we found a significant improvement in CRT
on OCT and BCVA, study design and population varied
across studies and this variation was reflected in significant
heterogeneity in the estimated comparative effect for the
analysis of both BCVA and CRT. We found that the type of
study had a significant impact on our results when analyzing
BCVA, supporting the view that information gathered from
prospective studies may offer clearer conclusions and that
overinterpretation of retrospective studies should be avoided.
Sensitivity and subgroup analysis of only high quality studies
did not reveal any difference in the results and suggests
that these results indeed represent the culmination of all
current studies. The main strength of our meta-analysis is in
incorporating all previous studies, resulting in a large sample
size and allowing us to focus the results of all previous studies.
5. Conclusions
To date, this is the first systematic meta-analysis evaluating
the visual and anatomical outcomes of patients with resistant
AMD converted to aflibercept. Our analysis provides sub-
stantial evidence that following switching there is a significant
anatomical effect, resulting in CRT thinning. However, the
visual function change was far more modest and while there
is evidence to support that aflibercept has a comparable
effect to other anti-VEGF agents in maintaining vision, any
potential significant benefit should be regarded with caution.
While this study has clarified the known effect of aflibercept
in treatment failure neovascular AMD eyes, future results,
especially from prospective studies, may offer new insights
into the different effects of these agents.
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